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Abstract Degradation of cyclin B and cyclin-dependent kinase
inhibitor, p27, at a specific time has been shown to play a critical
role in regulating the cell cycle. SPase, a nuclear and cytosol
protease with cathepsin B- and L-like proteolytic activity, has
been identified in several cell lines. This proteolytic enzyme
selectively degraded nuclear proteins such as retinoblastoma
susceptibility gene product, RB, and transcription factor, SP-1.
High levels of SPase activity were detected at the G1/S,
moderate levels at the G1 and S phases, and undetectable
activity at the M phase of synchronized CV-1 cells, suggesting
that SPase activity is regulated through the cell cycle.
Degradation of RB correlated with SPase activity throughout
the cell cycle, suggesting that SPase regulates RB, which has a
functional role in regulating cell cycle. These results demon-
strated that SPase plays an integral role in regulating the nuclear
regulator, RB, in controlling cell cycle progression.
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1. Introduction
The balance between protein synthesis and degradation
controls levels of cellular proteins. Cellular proteolysis is not
only important for scavenging excess proteins, but also regu-
lates gene expression, the cell cycle, apoptosis and cellular
stress responses [1^3]. Protein degradation occurs by either
lysosomal or non-lysosomal mechanisms [4]. One major fam-
ily of lysosomal proteases is the cysteinyl proteases, which
include cathepsin B, H, and L [5].
E¡ects of thiol or serine protease inhibitors on cell cycle
and cell proliferation have been reported [6,7]. Although a
role for intracellular proteases in the regulation of cell growth
has been proposed [8], little evidence is currently available.
Three trypsin-like proteases have been suggested to function
at the G1, S and G2 phases in HeLa cells [9]. Proteolysis of
important proteins involved in cell cycle functions, such as
cyclin B and cyclin-dependent kinase inhibitor p27, is crucial
in regulating cell cycle progression in a wide variety of cell
types [10^12]. It has also been demonstrated that inactivation
of calpain results in enhanced stability of the p53 protein that
mediates downstream e¡ects such as cell cycle arrest and
apoptosis [13]. Recently, we puri¢ed and characterized a
unique cathepsin-like protease, SPase, which selectively de-
grades important nuclear regulators such as transcription fac-
tor SP-1 and the retinoblastoma susceptibility gene product,
RB [14]. Thus, a possible role for SPase is to a¡ect the stabil-
ity of important regulators involved in controlling cellular
proliferation.
A speci¢c protease, SPase, was isolated from nuclear ex-
tracts of the green monkey kidney cell line, CV-1 [14]. Studies
of biochemical characteristics and substrate speci¢city indicate
that SPase is a cathepsin B-like cysteinyl protease [14]. How-
ever, the two tryptic peptide sequences derived from the pu-
ri¢ed SPase are either identical or highly homologous to those
of human cathepsin L, and share immunoreactivity with both
anti-human cathepsin L and mouse cathepsin L antibodies
[14]. SPase is localized to both cytoplasmic and nuclear frac-
tions. Transcription factor SP-1 and the retinoblastoma sus-
ceptibility gene product, RB, are substrates of SPase, while
other nuclear factors such as c-Jun and c-Fos are not. These
results imply that SPase plays an integral role in regulating a
set of proteins in the nuclei.
RB is a nuclear phosphoprotein that exhibits cell cycle-de-
pendent alterations in its phosphorylation state [15^17]. Mi-
croinjection of the full-length or carboxyl-terminal half of the
protein into cells inhibits G1 phase progression, suggesting
that RB may function during the early G1 phase [18]. Involve-
ment of RB at the G2 and M phases of the cell cycle has also
been recently suggested [19^21]. The extent of RB phospho-
rylation varies with the progression of cells through the cell
cycle, suggesting that phosphorylated RB results in inactiva-
tion of RB function, thereby allowing cell proliferation [18].
The physiological interaction of D-type cyclins with RB may
therefore help to direct cyclin-dependent kinases (cdks) to this
substrate, resulting in RB phosphorylation at multiple sites
and subsequent destabilization of the multimeric complexes
[22^24]. Speci¢c phosphatase acting on RB in the late stages
of mitosis is also important for dephosphorylation [25].
In addition to being phosphorylated in a cell cycle-depend-
ent manner, RB expression may be regulated at the post-tran-
scriptional level [26]. This could be either at the level of trans-
lational control or protein turnover. It has been reported that
ubiquitin-dependent proteolysis is involved in E7-E6- or E7-
mediated degradation of RB [27,28]. These results raise the
possibility that degradation of RB under certain conditions
can be an alternative pathway to inactivate the normal func-
tion of RB in constraining cell growth.
SP-1 is a protein that activates transcription of viral and
cellular genes that contain at least one SP-1 binding site con-
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sisting of a GC-rich decanucleotide sequence, 5P-GGGGCG-
GGGC-3P (GC-box), within their transcriptional control re-
gions [29^31]. It has been shown that SP-1 is in both glyco-
sylated and phosphorylated form [32,33], but it is still unclear
whether these post-translational modi¢cations play an impor-
tant role in regulating SP-1-mediated transcription. Neverthe-
less, SV40-infected CV-1 cells show an increased amount of
phosphorylated SP-1 by a dsDNA-dependent kinase [33].
Under certain physiological and biochemical conditions,
phosphorylated SP-1 may in£uence the transcriptional initia-
tion event and its intracellular stability by facilitating turnover
by a speci¢c protease [33].
RB is one of the substrates for SPase both in vitro and in
vivo [14]. It is of interest to determine whether SPase is in-
volved in cell cycle regulation by degradation of RB. In this
report, we demonstrate that SPase activities are regulated
through the cell cycle. Degradation of RB parallels SPase
activity throughout the cell cycle. These results demonstrated
that proteolysis of RB is a novel mechanism for controlling
cell cycle progression.
2. Materials and methods
2.1. Materials
Aphidicolin, nocodazole, (2S,3S)-trans-epoxysuccinyl-L-leucylami-
do-3-methyl-butane ethyl ester (E-64d) and N-acetylleucylleucylnor-
leucinal (ALLN) were obtained from Sigma Inc. (St. Louis, MO).
Isoleucine-free MEM select-amine kit, 5-bromo-4-chloro-3-indolyl-
phosphate (BCIP) and nitroblue tetrazolium chloride (NTB) were
purchased from Gibco/Bethesda Research Laboratories (Gaithers-
burg, MD). Anti-RB (IF8) and anti-SP-1 (PEP2) antibodies were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Prestained sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE)
standards were obtained from Bio-Rad (Hercules, CA), and ECL
developing reagents were obtained from Amersham Life Science (Ar-
lington Heights, IL). All other chemicals were of analytical grade.
2.2. Cell culture
CV-1 cells (green monkey kidney cell line), COS-1 cells (simian
virus 40-transformed CV-1 cells) and BSC-1 cells (green monkey kid-
ney cell line) were grown in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum. Cells were grown
at 37‡C in a humidi¢ed incubator with 6% CO2.
2.3. Synchronization of cells
Cells were synchronized at the G1 phase by isoleucine starvation for
48^60 h, then incubated with a complete medium supplemented with
5 Wg/ml of aphidicolin for an additional 16 h to synchronize cells at
the G1/S boundary [34]. Cells were released from the G1/S boundary
by washing three times with phosphate bu¡ered saline (PBS) and
refeeding with the complete medium. Six h after the removal of
aphidiocolin, cells were arrested at the S phase. M phase-arrested
cells were collected after an additional 12^16 h of treatment with
0.04 Wg/ml of nocodazole [35].
2.4. Oligonucleotides and electrophoretic mobility shift assays (EMSA)
Oligonucleotides of the wild-type human c-jun Sp-1 sequence, 5P-
TGACGGGCGGGCCCGCCCCCCT-3P, were synthesized, depro-
tected, then puri¢ed through a Sephadex G-25 spin column. Comple-
mentary oligonucleotides were annealed and labeled at their 5P ends
using [Q-P32]ATP (4500 Ci/mmol; ICN Biochemicals, Inc., CA) and
T4 polynucleotide kinase (Promega, WI). Radiolabeled double-
stranded oligonucleotides were puri¢ed through a Sephadex G-25
spin column. The speci¢c activity of the oligonucleotide probes was
typically 105 cpm/ng of DNA. Probes were stored at 320‡C. For
assay of SPase activity, EMSAs were performed as previously de-
scribed [36].
2.5. Western blot analysis
Aliquots of nuclear extracts or recombinant proteins were electro-
phoresed on an SDS-PAGE and transferred to nitrocellulose mem-
branes. Membranes were probed with the anti-RB antibody, followed
by a secondary antibody of either horseradish peroxidase- or alkaline
phosphatase-conjugated goat anti-mouse immunoglobulin G. Immu-
noreactive bands were detected with either 5-bromo-4-chloro-3-indo-
lylphosphate (BCIP) and nitroblue tetrazolium chloride (NBT) or
ECL developing reagents.
3. Results
3.1. Evidence for the proteolytic activity of SPase in CV-1 cells
We have demonstrated that transcription factor SP-1 and
the retinoblastoma susceptibility gene product, RB, are sub-
strates of SPase puri¢ed from CV-1 cell nuclear extracts [14].
To examine the e¡ect of SPase on SP-1 binding activity, we
performed electro-mobility shift assay (EMSA) with incubated
CV-1 cell nuclear extracts prepared in the presence of mem-
brane-permeable cysteinyl protease inhibitor, E-64d or
ALLN, and COS-1 cell nuclear extracts containing SP-1.
We observed intact SP-1 binding activity in the nuclear ex-
tracts prepared from the E-64d- or ALLN-pretreated CV-1
cells (Fig. 1A, lanes 3 and 4), suggesting that the protease
inhibitor diminishes proteolytic activity of SPase in vivo and
prevents proteolytic degradation of cellular proteins such as
SP-1. The speci¢city of protease inhibitors to inhibit SPase
activity was con¢rmed by the addition of anti-cathepsin L
antibody to depletion of SPase since anti-cathepsin L anti-
body cross-hybridized with SPase [14]. The SPase-depleted
CV-1 nuclear extracts failed to inhibition of SP-1 binding
(data not shown), suggesting that the inhibition of SP-1 bind-
ing observed initially was due to the proteolytic activity of the
SPase. To explore the signi¢cance of SP-1 degradation by
SPase activity in vivo, we examined the integrity of RB in
the nuclear extracts prepared from permeable cysteinyl pro-
tease inhibitor-pretreated CV-1 cells by Western blotting using
the anti-RB (IF-8) antibody. IF-8 antibody was directed
against RB amino acid residues 300^380. As shown in Fig.
1B (lanes 2 and 3), either E-64d- or ALLN-treated CV-1 nu-
clear extracts, prepared in the absence of leupeptin, remained
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Fig. 1. Detection of SPase activity in the CV-1 cells. A: Four mi-
crograms of COS-1 nuclear extracts were used in an EMSA with
the hcj-Sp-1 probe (lane 1). A mixture of COS-1 and CV-1 nuclear
extracts (4 Wg each) was used in EMSA as a control (lane 2). CV-1
nuclear extracts prepared from cells treated with E-64d (50 Wg/ml)
or with ALLN (50 WM) for 5 h were used in lanes 3 and 4, respec-
tively. B: Western blot analysis of RB degradation. CV-1 cells were
grown in the absence or presence of E-64d (50 Wg/ml) or ALLN (50
WM) for 24 h. The nuclear extracts were then prepared in the pres-
ence or absence of a protease inhibitor, leupeptin, as indicated. Ten
micrograms of each nuclear extract were analyzed by the Western
blot analysis probed with the anti-RB antibody (lanes 1^3).
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an intact RB with truncated 78-kDa proteins, but not the
SPase-degraded 50-kDa fragment. In contrast, non-E-64d-
or ALLN-treated extracts prepared in the presence of leupep-
tin, to prevent further degradation in vitro, generated the
SPase-degraded 50-kDa fragment (Fig. 1B, lane 1). Therefore,
SPase activity in CV-1 cells appears to be e¡ectively inhibited
by the permeable cysteinyl protease inhibitors, E-64d or
ALLN, suggesting that SPase is indeed involved in both RB
and SP-1 turnover in vivo.
3.2. SPase is an RB binding protein
Previous and the above studies indicated that the RB pro-
tein is a substrate for the speci¢c protease, SPase. To provide
further evidence that SPase binds to RB to form an enzyme-
substrate complex, the glutathion S-transferase (GST)-RB
(379^928) fusion protein and its various mutants, GST-RB
(379^928, dl573^645), GST-RB (379^928, dlExon21) and
GST-RB (379^928, dlExon22), were linked to glutathion se-
pharose for SPase binding analysis. GST-2T sepharose or se-
pharose alone was used as a negative control (Fig. 2, lanes 4
and 5). CV-1 nuclear extracts containing SPase activity were
incubated at 4‡C for 1/2 h with sepharose beads carrying
various GST-RB fusion proteins. Proteins speci¢cally binding
to the beads were eluted with 1.0 M of KCl after extensive
washing. Eluted fractions were dialyzed against EMSA bind-
ing bu¡er. One-third of the dialyzed samples were used for the
e¡ect of SP-1 binding assay with EMSA containing the hcj-
Sp-1 probe [35]. These results demonstrated that 1.0 M of
KCl eluent from GST-RB (379^928), GST-RB (379^928,
dl573^645) or GST-RB (379^928, dlExon22) sepharose con-
tains SPase activity su⁄cient to abolish SP-1 binding (Fig. 2,
lanes 3, 6 and 8). In contrast, 1.0 M of KCl eluent from GST-
RB (379^928, dlExon21) failed to inhibit SP-1 binding (Fig. 2,
lane 7), suggesting that the RB exon 21 region is required for
interaction with SPase to form an enzyme-substrate complex.
3.3. The activity of SPase is regulated through the cell cycle
The RB protein is an important cell cycle regulator, and is
one of the substrates of SPase. To determine whether SPase
activity is also regulated through the cell cycle, CV-1 cells
were synchronized, and the activities of SPase were measured
at di¡erent stages of the cell cycle. As shown in Fig. 3, high
levels of SPase activity in synchronized CV-1 cells were de-
tected at G1/S, moderate levels at the G1 and S phases, and no
detectable levels at the M phase, suggesting that SPase activity
is regulated through di¡erent phases of the cell cycle. The
extent of synchronization of the cells was indicated by £ow
cytometry data, as shown in Fig. 3. The CDK2 protein has
been expressed constitutively throughout the cell cycle in sev-
eral cell lines [37]. We therefore examined the CDK2 protein
levels as internal controls by Western blot analysis (Fig. 3,
lower panel). Another green monkey kidney cell line, BSC-1,
gave results similar to those of CV-1 cells (data not shown).
Thus, SPase activity is regulated at di¡erent stages of the cell
cycle.
3.4. Proteolysis of the RB or SP-1 proteins in SPase-containing
cells is cell cycle stage dependent
To determine whether the level of RB or SP-1 correlates
with the activity of SPase throughout the cell cycle, we exam-
ined the integrity of both RB and SP-1 at the di¡erent stages
of synchronized CV-1 cells. Nuclear extracts from each stage
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Fig. 3. Inhibition of SP-1 binding activity by CV-1 cell nuclear ex-
tracts from di¡erent stages of the cell cycle. The hcj-Sp-1 probe was
used in the EMSA. Four micrograms each of nuclear extracts were
subjected to EMSA, including COS-1 nuclear extract as control
(lane 1), CV-1 nuclear extracts prepared from the G1 phase (lane 2),
the G1/S block (lane 3), the S phase (lane 4), and the M phase
(lane 5). CV-1 cells were synchronized as described in Section 2.
The proportions of cells at di¡erent stages of the cell cycle in the
synchronized CV-1 cells (data from FACS) are indicated below the
EMSA. As shown in the bottom panel, equal amounts of CDK2
proteins were detected by Western blot analysis in 10 Wg of CV-1
nuclear extracts prepared from the G1, G1/S, S and M phases of
the cell cycle.
Fig. 2. SPase is a RB binding protein. Thirty micrograms of CV-1
nuclear extracts were incubated at 4‡C for 1/2 h with 300 Wl of glu-
tathion S-transferase (GST)-sepharose beads immobolized with
GST-RB (379^928) and its various mutants, GST-RB (379^928,
dl573^645), GST-RB (379^928, dlExon21) or GST-RB (379^928,
dlExon22). Proteins binding speci¢cally to the beads were eluted
with 1.0 M of KCl after extensive washing with a bu¡er containing
20 mM HEPES (pH 7.9), 0.5 mM EDTA, 1 mM DTT, 1 mM
PMSF, 20% glycerol, and 0.1 M KCl. Eluted fractions were dia-
lyzed against EMSA binding bu¡er. One-third of the dialyzed sam-
ples were subjected to EMSA with hcj-Sp-1 probe to test the e¡ect
of SP-1 binding (lanes 3, and 6^8). The SP-1 DNA binding complex
from 4 Wg of COS-1 nuclear extracts and eluent from GST-2T se-
pharose or sepharose alone were used as controls for lack of SPase
activity (lanes 1, 4 and 5). CV-1 nuclear extracts inhibiting the SP-1
DNA binding complex recovered from COS-1 nuclear extracts were
used as a positive control for SPase activity (lane 2).
Y.-H.F. Fu et al./FEBS Letters 421 (1998) 89^93 91
of the cell cycle were prepared in the presence of 5 WM leu-
peptin to prevent further degradation by SPase in vitro. The
integrity of RB and SP-1 in vivo was analyzed using Western
blot from the nuclear extracts prepared above, and probed
with the anti-RB or the anti-SP-1 antibody (Fig. 4A and B).
As shown in Fig. 4A, the RB protein was highly or partially
degraded to a 50-kDa fragment in the nuclear extracts pre-
pared at the G1, G1/S, or S phases (Fig. 4A, lanes 5, 6 and 7).
In contrast, the RB protein retained intact without resulting in
a degraded 50-kDa RB fragment at the M phase (Fig. 4A,
lane 8). In COS-1 cells, which have undetectable SPase activ-
ity, the RB protein remained intact and at a constant level
throughout the cell cycle (Fig. 4A, lanes 1^4). Similarly, al-
most undetectable levels of SP-1 proteins were observed in
nuclear extracts prepared at the G1, G1/S and S phases
(Fig. 4B, lanes 5^7), as compared with a high level of intact
SP-1 at the M phase (Fig. 4B, lane 8). Expression of SP-1
throughout the cell cycle also remained unchanged in COS-1
cells (Fig. 4B, lanes 1^4). These results are consistent with
those regarding the regulation of SPase activity during cell
cycle progression, suggesting that degradation of RB or SP-
1 by SPase is also cell cycle stage dependent in CV-1 cells.
4. Discussion
The cell cycle is a highly regulated event, and all steps of
progression through the cell cycle must be rigorously con-
trolled [10]. Emerging evidence suggests that in all cells, ser-
ine/threonine kinases and proteasomes involved in phospho-
rylation and degradation of cyclins, respectively, are central to
control of the cell cycle [12,38,39]. SPase, a cathepsin-like
enzyme, has been localizing to the cytoplasm and the nucleus
in several cell lines [14]. The involvement of the cathepsins in
degradation of highly active regulatory proteins [40^42] led to
the hypothesis that SPase rapidly degrades short-lived nuclear
regulatory proteins, and thus plays an important role in reg-
ulation of the cell cycle.
In this report, we demonstrate that proteolysis of the RB
protein by a newly identi¢ed cathepsin-like nuclear protease,
SPase, is regulated throughout the cell cycle in SPase-contain-
ing cell lines such as CV-1, BSC-1, MDCK and MDOK (Fig.
3 and Fu et al., unpublished data). The activities of SPase
parallel the degradation of the RB protein at the G1, G1/S
and S phases of synchronized CV-1 cells (Fig. 4A). In con-
trast, no detectable SPase activity (Fig. 3, lane 5) without the
degraded 50-kDa RB was observed at the M phase of the cell
cycle (Fig. 4A, lane 8). A similar result was also observed
when SP-1 was analyzed by Western blotting of nuclear ex-
tracts prepared from synchronized cells (Fig. 4B, lane 8).
These results suggested that SPase regulates cell cycle media-
ting proteolysis of RB.
The E2F-1 protein is a transcription factor that regulates
several genes involved in DNA synthesis during the cell cycle
[43]. It is known that E2F-1 interacts with an underphos-
phorylated form of RB at the G1 phase of the cell cycle
[44]. Upon phosphorylation of RB at the G1/S block, the
E2F-1-RB complex becomes dissociated, and the free E2F-1
molecule turns on the progression of the cell cycle to the S
phase [45]. Our previous data [14] demonstrated that SPase
preferentially digests hyperphosphorylated RB. Therefore,
high levels of SPase activity at the G1/S phase could be im-
portant in removing hyperphosphorylated RB at this speci¢c
stage. Furthermore, with a limited proteolysis of RB, the
cleaved or truncated RB species retain their functions as
underphosphorylated RB and still interact with E2F-1. How-
ever, after severe proteolysis of RB, the degraded RB may
release the cell from the G1/S block, which is analogous to
the function of the phosphorylated RB (Fu et al., unpublished
data). Therefore, the degree of RB proteolysis may generate a
di¡erent pathway for the progression of the cell cycle in cer-
tain cell types.
Degraded RB with a fragment of approximately 60 kDa has
been observed in TPA-treated U937 cells [46] or in a retinoic
acid-treated non-small cell lung carcinoma cell line [47]. More-
over, instability of exogenously expressed RB in the prolonged
culture of reconstituted retinoblastoma cells has been impli-
cated in the loss of tumorigenic suppression function [48].
Recently, it has been reported that hypophosphorylated RB
in the anti-cancer drug-treated HL-60 and U937 cells is
cleaved into 68- and 48-kDa fragments by an interleukin
1B-converting enzyme-like protease [49]. The RB cleavage is
also tightly associated with the initiation of apoptosis, sug-
gesting that a protease may be involved in mediating apopto-
sis [50,51]. In addition, Hinds et al. [52] reported that ectopic
expression of cyclin D1 can overcome RB-induced growth
arrest but not cause RB phosphorylation, suggesting that
RB can be regulated by mechanisms other than phosphoryla-
tion for growth control. Therefore, the ¢ndings in this report
suggest that the speci¢c proteolysis of RB by SPase is one of
the mechanisms involved in controlling cell cycle progression.
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Fig. 4. Degradation of the RB and SP-1 proteins at di¡erent stages of the cell cycle in CV-1 cells. Equal amounts (15 Wg) of nuclear extract
proteins from COS-1 and CV-1 cells synchronized at the G1, G1/S, S or M phases of the cell cycle were loaded onto a 10% SDS-PAGE (lanes
1^4 for COS-1 cells, and lanes 5^8 for CV-1 cells). Western blot analysis was performed probing with the anti-RB antibody (panel A) or the
anti-SP-1 antibody (panel B).
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There are several potential explanations for how SPase reg-
ulates cell cycle progression through proteolysis of RB. Since
phosphorylated RB has been suggested to be a preferential
substrate for SPase [13], SPase could be one controlling factor
for the levels of phosphorylated RB at di¡erent stages of the
cell cycle, and might therefore regulate cell cycle function. In
this case, the interplay of RB with other regulatory proteins
involved in cell cycle control, such as D cyclins or E2F-1,
could be altered when RB is in a truncated form. The trun-
cated and degraded forms of RB may act as dominant-neg-
ative mutants to compete for the normal function of RB in
regulating the cell cycle. In addition, over-expression of RB
has been reported to possibly cause G2/M arrest [53]. Thus,
SPase could regulate cell cycle progression at the G2/M check-
point by removing the excess RB prior to the G2/M phase.
Finally, the absence of SPase activity and RB degradation at
the M phase of the cell cycle may be important for mitosis
and the continuation of the next cell cycle. To further test
these possibilities and de¢ne the biological functions of de-
graded RB by SPase in the cell cycle control, the e¡ects of
the exogenously expressed SPase gene in COS-1 cells on cell
cycle progression are currently being investigated.
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